Richard Peters is een zwaargewicht gezien zijn eerdere functies en CEO ervaringen,
waaronder die bij Sanofi/Genzyme met focus op oncologie.
Past volgens mij prima in het straatje binnen de tumor-verkleinende eigenschap van Leniolisib.
In his role at Sanofi Genzyme, he was responsible for a global, $3 billion per year business
with 10 commercialized products and a robust, multi-product development pipeline focusing on several therapeutic areas.
He is an expert in the field of Oncology, previously serving as Division Medical Officer at Sanofi Oncology,
and is the former Head of Global and US Medical Affairs at Genzyme Transplant/Oncology.
He has also served as a Senior Director at Onyx Pharmaceuticals,
as a Director at Amgen, and as Chief Executive Officer of Mednav
Kost een paar centen, maar dan heb je ook wat.